CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

CAR T-cell Therapy CYAD-101 No Longer Under Development for Metastatic CRC

October 14th 2022

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.

GPRC5D Antigen–Targeted CAR T-cell Therapy Induces Strong Response in Resistant Multiple Myeloma

October 3rd 2022

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma

September 28th 2022

The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.

Gavo-cel Elicits Clinical Benefit in Solid Tumors, Including Ovarian Cancer and Mesothelioma

September 28th 2022

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

Dr. Paul on the Management of CRS and ICANS After CAR T-cell Therapy in Cancer Care

September 27th 2022

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Zevor-cel Elicits 100% ORR in Heavily Pretreated Relapsed/Refractory Myeloma

September 22nd 2022

The BCMA-directed CAR T-cell therapy zevorcabtagene autoleucel demonstrated a 100% objective response rate in heavily pretreated patients with relapsed/refractory multiple myeloma

CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors

September 9th 2022

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL

August 22nd 2022

Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20th 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

CART-ddBCMA Generates Deep Responses in Relapsed/Refractory Multiple Myeloma

August 19th 2022

Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.

Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

August 17th 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

FDA Approves Beti-cel for β-thalassemia Requiring Transfusions

August 17th 2022

The FDA has approved betibeglogene autotemcel (Zynteglo) for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Anbalcabtagene Autoleucel Shows Promise in Relapsed/Refractory LBCL

August 17th 2022

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Dr. Shah on How to Address CAR T-Cell Therapy Failure in Hematologic Malignancies

August 16th 2022

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Ide-cel Produces PFS Benefit Vs Standard Regimens in Relapsed/Refractory Multiple Myeloma

August 10th 2022

Idecabtagene vicleucel elicited a statistically significant improvement in progression-free survival vs standard combination regimens in patients with relapsed/refractory multiple myeloma who had received 2 to 4 lines of prior therapy.

CAR T-cell Therapy CT103A Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 3rd 2022

The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC

August 1st 2022

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.